JP2007533733A - 食物摂取管理の方法 - Google Patents

食物摂取管理の方法 Download PDF

Info

Publication number
JP2007533733A
JP2007533733A JP2007509061A JP2007509061A JP2007533733A JP 2007533733 A JP2007533733 A JP 2007533733A JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007533733 A JP2007533733 A JP 2007533733A
Authority
JP
Japan
Prior art keywords
route
subject
betahistine
agonist
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007509061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533733A5 (enExample
Inventor
ニル バラク，
Original Assignee
モル リサーチ アプリケーションズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL16159504A external-priority patent/IL161595A0/xx
Application filed by モル リサーチ アプリケーションズ リミテッド filed Critical モル リサーチ アプリケーションズ リミテッド
Publication of JP2007533733A publication Critical patent/JP2007533733A/ja
Publication of JP2007533733A5 publication Critical patent/JP2007533733A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2007509061A 2004-04-22 2005-04-21 食物摂取管理の方法 Pending JP2007533733A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16159504A IL161595A0 (en) 2004-04-22 2004-04-22 Betahistine as a weight management agent
US67029005P 2005-04-12 2005-04-12
PCT/IL2005/000440 WO2005101979A2 (en) 2004-04-22 2005-04-21 Method of food intake management

Publications (2)

Publication Number Publication Date
JP2007533733A true JP2007533733A (ja) 2007-11-22
JP2007533733A5 JP2007533733A5 (enExample) 2008-05-29

Family

ID=35197421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007509061A Pending JP2007533733A (ja) 2004-04-22 2005-04-21 食物摂取管理の方法

Country Status (10)

Country Link
US (5) US20060084686A1 (enExample)
EP (1) EP1737454A4 (enExample)
JP (1) JP2007533733A (enExample)
KR (1) KR20060134041A (enExample)
BR (1) BRPI0506807A (enExample)
CA (1) CA2553309A1 (enExample)
EA (1) EA200601414A1 (enExample)
IL (1) IL176793A0 (enExample)
NO (1) NO20063221L (enExample)
WO (1) WO2005101979A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506930A (ja) * 2017-02-02 2020-03-05 オトラーヌム アーゲー ベタヒスチンを含む鼻腔内組成物

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005101979A2 (en) 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
UA98938C2 (ru) * 2006-06-16 2012-07-10 Теракос, Инк. Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
ES2830073T3 (es) * 2007-04-11 2021-06-02 Omeros Corp Composiciones y métodos para la profilaxis y el tratamiento de adicciones
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
US8586634B2 (en) * 2007-06-15 2013-11-19 University Of Florida Research Foundation, Inc. Therapeutic compounds
US8642631B2 (en) 2008-05-27 2014-02-04 University Of Melbourne Methods of treating mammals with eustachian tube dysfunctions
WO2011009012A1 (en) * 2009-07-15 2011-01-20 Columbia University METHODS OF SUPPRESSING APPETITE BY THE ADMINISTRATION OF ANTAGONISTS OF THE SEROTONIN HTR1a or HTR2b RECEPTORS OR INHIBITORS OF TPH2
US20110021507A1 (en) * 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
PH12012500628A1 (en) * 2009-10-13 2012-10-22 Nestec Sa Systems for evaluating dietary intake and methods of using same
SMT201900357T1 (it) 2009-12-04 2019-07-11 Alkermes Pharma Ireland Ltd Derivati di morfinano per trattamento di abuso di sostanze stupefacenti
US20110143704A1 (en) 2009-12-14 2011-06-16 William Lorentz Specialized dial a chip
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
NZ631018A (en) 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
RU2540911C2 (ru) * 2013-06-11 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами
DE102015202695A1 (de) * 2015-02-13 2016-08-18 Carl Zeiss Smt Gmbh Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR20250154480A (ko) * 2023-02-28 2025-10-28 바이오하벤 테라퓨틱스 리미티드 강박 관련 장애, 틱 장애 및 글루타메이트 흥분독성 관련 장애의 치료 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
JP2003500353A (ja) * 1999-05-19 2003-01-07 アストラゼネカ・アクチエボラーグ 処置方法
JP2003528829A (ja) * 2000-03-08 2003-09-30 アーヴェーデー．ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 薬剤学的製剤
JP2004501957A (ja) * 2000-06-29 2004-01-22 レナーツ，ビンセンツ 徐放性医薬製剤に利用する架橋高アミローススターチとその製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577871A (en) * 1976-05-28 1980-10-29 Unimed Inc Prevention of myocardial infarction
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
WO2000039098A1 (en) * 1998-12-23 2000-07-06 Maxim Pharmaceuticals, Inc. Synthesis of histamine dihydrochloride
IT1309591B1 (it) 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
CA2444429A1 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
US20040110803A1 (en) 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2005101979A2 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
US20060039866A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
JP2003500353A (ja) * 1999-05-19 2003-01-07 アストラゼネカ・アクチエボラーグ 処置方法
JP2003528829A (ja) * 2000-03-08 2003-09-30 アーヴェーデー．ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 薬剤学的製剤
JP2004501957A (ja) * 2000-06-29 2004-01-22 レナーツ，ビンセンツ 徐放性医薬製剤に利用する架橋高アミローススターチとその製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5007006067, ＲＯＳＳＩ, ＰＨＹＳＩＯＬＯＧＹ ＆ ＢＥＨＡＶＩＯＩＲ, 1999, Ｖ６６ Ｎ３, Ｐ５１７−５２１ *
JPN5007006068, ＳＺＥＬＡＧ, ＰＯＬＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＯＬＯＧＹ．, 2001, Ｖ５３, Ｐ７０１−７０７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506930A (ja) * 2017-02-02 2020-03-05 オトラーヌム アーゲー ベタヒスチンを含む鼻腔内組成物

Also Published As

Publication number Publication date
NO20063221L (no) 2006-10-06
US7737165B2 (en) 2010-06-15
WO2005101979A3 (en) 2006-07-27
US20060073217A1 (en) 2006-04-06
EA200601414A1 (ru) 2007-02-27
US20080004322A1 (en) 2008-01-03
IL176793A0 (en) 2006-10-31
US20080051439A1 (en) 2008-02-28
CA2553309A1 (en) 2005-11-03
WO2005101979A2 (en) 2005-11-03
BRPI0506807A (pt) 2007-05-29
US20060084686A1 (en) 2006-04-20
EP1737454A4 (en) 2007-08-08
US20080004324A1 (en) 2008-01-03
EP1737454A2 (en) 2007-01-03
KR20060134041A (ko) 2006-12-27

Similar Documents

Publication Publication Date Title
JP2007533733A (ja) 食物摂取管理の方法
US20100152161A1 (en) Compositions for weight management
US7834056B2 (en) Pharmaceutical composition for gout
ES2654787T3 (es) Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento
BRPI0914985B1 (pt) Composição para administração oral de baixa dose de topiramato/fentermina
JPH05507731A (ja) 物質乱用障害の治療用医薬組成物
TW201136916A (en) New uses
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
WO2004080444A2 (en) Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
EP0923370A2 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
AU758181B2 (en) Therapeutic agents
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
CN108463224A (zh) sGC刺激剂用于胃肠功能障碍治疗的应用
US20060293309A1 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
CN1291092A (zh) 含有曲马朵的药物组合物
JP2022525202A (ja) 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量
WO2014199294A1 (en) Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
CN101610760A (zh) 恶病质的治疗
US7223754B2 (en) Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
US20080051440A1 (en) Compositions for weight management
TW567068B (en) Medicinal compositions for treating lower uropathy
Aminoff Basic & clinical pharmacology
MX2010006520A (es) Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
AU2006202950A1 (en) Methods and Compositions for Weight Management
MXPA06007693A (en) Method of food intake management

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110628